Type 2 & other diabetes

Protective effects of 23‐valent pneumococcal polysaccharide vaccination against mortality among elder patients with type 2 diabetes mellitus

Diabet MedPublished Retrospective cohort study

Main finding · All-cause mortalityResult — go to the resultAdjusted hazard ratio 0.47 95% CI 0.42–0.53

Authors' conclusion

PPSV23 vaccination is associated with a reduced risk of all cause mortality, cardiovascular disease-related mortality, pneumonia-related mortality and cancer mortality in elderly people with type 2 diabetes mellitus.

Study context

Population
Elderly people with T2D in Soochow, China
Participants
8,649 people
Exposure
Pneumococcal polysaccharide vaccine (PPSV23) vaccination vs unvaccinated
  • PPSV23n = 3,247
  • Unvaccinatedn = 5,402reference
Outcome
All-cause mortality
Methodological detailsCox proportional hazards, inverse probability weighting
  • Cox proportional hazards
  • Inverse probability weighting

Main finding

As reported in the abstract

Adjusted hazard ratio

0.47

95% CI 0.42–0.53

PPSV23vs Unvaccinated
aHR 0.47 (95% CI 0.42–0.53)
Deaths recorded during follow-up (total)
1557
All-cause deaths preventable by universal PPSV23 vaccination (inverse probability weighting (IPW) average treatment effect (ATE)), p < 0.001
11.4%

Observational data: associations, not effects.

Further findings

OutcomeaHR (95% CI)
CVD-related mortality0.50 (0.41–0.62)
Pneumonia-related mortality0.62 (0.43–0.89)
Cancer mortality0.54 (0.42–0.70)
CVD-related mortality — CVD-related deaths preventable (IPW ATE), p < 0.001
4.0%
Pneumonia-related mortality — Pneumonia-related deaths preventable (IPW ATE), p = 0.005
0.8%
Cancer mortality — Cancer deaths preventable (IPW ATE), p < 0.001
1.9%

Original publication

Protective effects of 23‐valent pneumococcal polysaccharide vaccination against mortality among elder patients with type 2 diabetes mellitus. Diabet Med. Published 30 April 2026. doi:10.1111/dme.70341

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.